RecruitingNCT02135705
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Sponsor
Amryt Pharma
Enrollment
300 participants
Start Date
Mar 18, 2014
Study Type
OBSERVATIONAL
Conditions
Summary
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Eligibility
Inclusion Criteria3
- Patients of all ages, including minors, who have initiated commercial treatment with lomitapide prior to or at time of registry enrolment.
- Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures or paediatric patients with the consent of a parent or legal guardian.
- Patients ≥7 years of age (or above the age determined by the IRB/EC and in accordance with the local regulations and requirements) must also provide written informed assent forms.
Exclusion Criteria2
- Patients who are receiving lomitapide in clinical trials or through compassionate use, where patients are followed under a separate protocol.
- Patients receiving an investigational agent, defined as any drug or biologic agent other than lomitapide that has not received market authorization in the country of participation, at time of lomitapide initiation and continuing to receive an investigational agent at time of registry enrolment. These patients may be enrolled if receiving lomitapide when the investigational agent is discontinued..
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLomitapide
As prescribed by Physician.
Locations(75)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02135705
Related Trials
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT0703777122 locations
HoFH, the International Clinical Collaborators Registry
NCT048150054 locations
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
NCT011093681 location
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
NCT061258471 location